GH Research PLC GHRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
-
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
-
Psychedelic stocks surge after Trump supports using drugs like LSD for mental health
-
A small company can now advance its psychedelic into Phase 3. Here's why that matters to other psychedelic biotechs.
-
GH Research Shares Up, Plans to Provide Update on New Drug Application
-
GH Research to Provide Update on New Drug Application
Trading Information
- Previous Close Price
- $29.13
- Day Range
- $27.50–30.59
- 52-Week Range
- $11.32–31.00
- Bid/Ask
- $28.61 / $31.25
- Shares Outstanding
- 68.61M
- Market Cap
- $1.97B
- Volume/Avg
- 637,506 / 290,315
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 73
- Website
- https://www.ghres.com
Valuation
|
Metric
|
GHRS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.76 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GHRS
|
|---|---|
Quick Ratio | 22.63 |
Current Ratio | 23.04 |
Interest Coverage | −1,939.23 |
Quick Ratio
GHRS
Profitability
|
Metric
|
GHRS
|
|---|---|
Return on Assets (Normalized) | −18.21% |
Return on Equity (Normalized) | −18.86% |
Return on Invested Capital (Normalized) | −20.10% |
Return on Assets
GHRS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|q^^<<?j | LOCK|@<Xc? | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|sz?tm^k | LOCK|p^K?% | $71B | |||
| argenx SE ADR
ARGX
| LOCK|cj^cCr | LOCK|x<p | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|X&vmd$L | LOCK|xZm | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<lV&X@ | LOCK|X^&R | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Ls&T#R# | LOCK|q?PJ# | $26B | |||
| Moderna Inc
MRNA
| LOCK|bzZ?Jsc | LOCK|ghg | $25B | |||
| Incyte Corp
INCY
| LOCK|d<ymg@> | LOCK|?^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?L<>^c | LOCK|N%> | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|V&Hx?<V | LOCK|rK! | $16B |
United States